Navigation Links
Accera, Inc. Donates $50,000 to the Alzheimer's Foundation of America for National Memory Screening Day
Date:10/24/2011

BROOMFIELD, Colo., Oct. 24, 2011 /PRNewswire/ -- Accera, Inc., a biotech company specializing in cognitive health, announced today the company has donated $50,000 to the Alzheimer's Foundation of America (AFA) for sponsorship of its "National Memory Screening Day" (NMSD) during National Alzheimer's Disease Awareness Month.  These funds will be used to further the AFA's efforts to educate and support individuals with Alzheimer's disease (AD) and their families, especially about the importance of early detection of memory problems.

Eric J. Hall, founding president and CEO of AFA, said, "We're grateful that despite the difficult economy, Accera continues to demonstrate its generous commitment to individuals and their families facing Alzheimer's disease now or in the future.  It's a public health crisis that requires corporate engagement."

NMSD, an annual initiative sponsored by AFA, provides free, confidential, memory screenings to individuals concerned about memory loss with the objective of early detection and intervention.  Qualified healthcare professionals offer the face-to-face screenings and distribute educational materials about memory concerns and successful aging in communities across the nation on November 15.

Samuel Henderson, Ph.D., vice president of research and development for Accera, stated, "On behalf of the Accera team, we're happy to contribute to AFA's ongoing efforts of helping those affected by Alzheimer's and raise awareness about the options available to patients and their caregivers."  He continued, "It's our hope that through continued awareness initiatives such as NMSD, we can better educate patients and their families about this devastating disease."

About Alzheimer's disease
AD significantly impacts millions of family members and other caregivers – mentally, physically and financially.  The national Family Caregiver Alliance estimates that approximately 80 percent of caregivers provide unpaid assistance seven days a week.  With the lack of innovative new medications for AD, both patients and caregivers are seeking alternatives to improve quality of life.

About Axona®
Axona is a first-in-class medical food for the clinical dietary management of the metabolic processes associated with mild-to-moderate Alzheimer's disease. Dispensed by prescription, Axona targets the metabolic deficiencies and imbalances associated with Alzheimer's disease by providing an alternative energy source for brain cells.  With simple administration and once-a-day convenience, Axona is complementary to current Alzheimer's disease therapies.  For more information about Axona, please visit www.about-axona.com or contact a doctor who is familiar with the product.

About Accera, Inc.  
Accera, Inc. is a privately held commercial-stage cognitive health company that developed and now markets Axona in the US.  Axona is a prescription-only medical food intended for the clinical dietary management of the metabolic processes associated with mild-to-moderate Alzheimer's disease.  In clinical trials, Axona has been shown to safely improve cognitive function and memory in AD patients.  Axona addresses the hypometabolism or defective metabolism of glucose that occurs in those areas of the brain that are involved in Alzheimer's disease.  Accera engages in research, development and commercialization of other clinical applications for Axona.

For more information about Accera, please visit www.accerapharma.com.Contacts:Accera, Inc.
(303) 999-3705
Bill Poncy
VP Commercial Development
bponcy@accerapharma.com

Tiberend Strategic Advisors, Inc.
(212) 827-0020
Andrew Mielach

amielach@tiberend.com
or
Madeleine Desmond

mdesmond@tiberend.com
'/>"/>

SOURCE Accera, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Accera, Inc. to Support the Alzheimers Foundation of Americas National Memory Screening Day Through On-line Awareness Effort
2. Accera, Inc. Launches Neuera Pharmaceuticals, Inc.
3. Accera, Inc. to Present at Upcoming Investor Conferences
4. Dr. Thomas Werner Elected to Accera, Inc.s Board of Directors
5. Accera, Inc. Sponsors Alzheimers Associations 2009 ICAD Conference
6. Accera, Inc. Completes $35 Million Series C Financing
7. The Center for Business Intelligence Donates to the American Red Cross, Matching Employee Contributions for Disaster Relief in Japan
8. Beta-Pro Donates Human Islet Cells to Diabetes Researcher
9. Vita-Tech International, Inc. Donates One Ton of Vitamins To Polio Treatment Centers in Guinea, West Africa
10. GeneGo Donates Proprietary Cytokine Pathway Maps to ISICR
11. SANYO Donates Air Purification Systems Effective Against Flu Viruses to New York Airports and Schools
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... ... ... Dr. Bob Harman, founder and CEO of VetStem Biopharma, Inc. ... event entitled “Stem Cells and Their Regenerative Powers,” was held on August 31st, ... was joined by two human doctors: Peter B. Hanson, M.D., Chief of Orthopedic Surgery, ...
(Date:10/10/2017)... PITTSBURGH, PA (PRWEB) , ... October 10, 2017 ... ... this year’s recipients of 13 prestigious awards honoring scientists who ... be presented in a scheduled symposium during Pittcon 2018, the world’s leading conference ...
(Date:10/9/2017)... , ... October 09, 2017 , ... ... four-tiered line of medical marijuana products targeting the needs of consumers who are ... of Kindred takes place in Phoenix, Arizona. , As operators of two successful ...
(Date:10/7/2017)... 2017  The 2017 Nobel Prize in Chemistry ... Dubochet, Joachim Frank and Richard ... microscopy (cryo-EM) have helped to broaden the ... community. The winners worked with systems manufactured by ... highly resolved, three-dimensional images of protein structures that ...
Breaking Biology Technology:
(Date:4/5/2017)... 4, 2017 KEY FINDINGS The ... at a CAGR of 25.76% during the forecast period ... primary factor for the growth of the stem cell ... MARKET INSIGHTS The global stem cell market ... and geography. The stem cell market of the product ...
(Date:3/30/2017)... KONG , March 30, 2017 The ... a system for three-dimensional (3D) fingerprint identification by adopting ground breaking ... into a new realm of speed and accuracy for use in ... at an affordable cost. ... ...
(Date:3/27/2017)... ROCKVILLE CENTRE, N.Y. , March 27, 2017 ... by Healthcare Information and Management Systems Society (HIMSS) ... Analytics Outpatient EMR Adoption Model sm . In ... top 12% of U.S. hospitals using an electronic ... recognized CHS for its high level of EMR ...
Breaking Biology News(10 mins):